Literature DB >> 2457439

Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen.

O S Bruland1, O Fodstad, A E Stenwig, A Pihl.   

Abstract

The characteristics of a new osteosarcoma-associated cell surface antigen were studied by means of two murine monoclonal antibodies, TP-1 and TP-3, which were found to bind to two different epitopes on the same antigen, a monomeric polypeptide with a molecular weight of approximately 80,000. Immunohistochemical studies showed that the antigen was present in all osteogenic sarcomas tested, in most cases of malignant fibrous histiocytoma, in two malignant hemangiopericytomas and in a few synovial sarcomas, but not in other main groups of sarcomas and nonsarcomatous malignancies. In normal tissues it was detected only in clusters of cells in the adrenal medulla and in proximal kidney tubules. Also endothelial cells in proliferating capillaries in placenta and in most tumors were stained. The antigen was absent in resting but present in actively proliferating osteoblastic cells. The epitopes were resistant to proteolytic and sugar-cleaving enzymes but sensitive to high temperatures and could not be detected in paraffin-embedded specimens. The tissue distribution and properties of the antigen show that it is different from the sarcoma-associated antigens previously studied. In contrast to previous findings with three other anti-sarcoma monoclonal antibodies, no correlation was found between serum alkaline phosphatase activity and the amount of TP-binding substances in the same sera. Nevertheless, an apparently complex association between alkaline phosphatase and the TP-binding antigen seems to exist. Thus, the Mr 80,000 antigen extracted from an osteosarcoma cell line showed enzyme activity, whereas TP-binding molecules precipitated from patient sera contained alkaline phosphatase activity only in a few of the cases studied. Altogether our data suggest that the antigen defined by the TP antibodies may be a marker of osteoblastic differentiation. The pattern of antigen expression in malignant tumors is unique, inasmuch as the antigen is found selectively in sarcomas and in all 31 osteosarcomas tested.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2457439

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Anaplastic sarcoma of the mandible in a llama.

Authors:  E Malone; K Roertgen; C Kobluk
Journal:  Can Vet J       Date:  1996-07       Impact factor: 1.008

2.  Identification of a vitamin D-responsive protein on the surface of human osteosarcoma cells.

Authors:  S Shull; R P Tracy; K G Mann
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

Review 3.  Antibody-directed targeting of the vasculature of solid tumors.

Authors:  P E Thorpe; F J Burrows
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

4.  Intratumour injection of immunoglobulins labelled with the alpha-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay.

Authors:  R H Larsen; O S Bruland
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

5.  Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody.

Authors:  R H Larsen; O S Bruland; P Hoff; J Alstad; E K Rofstad
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

6.  Radioimmunotargeting of human tumour cells in immunocompetent animals.

Authors:  J G Fjeld; O S Bruland; H B Benestad; L Schjerven; T Stigbrand; K Nustad
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

7.  The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines.

Authors:  Eva Wessel Stratford; Jeanette Daffinrud; Else Munthe; Russell Castro; Jo Waaler; Stefan Krauss; Ola Myklebost
Journal:  Cancer Med       Date:  2013-12-17       Impact factor: 4.452

8.  MK3 modulation affects BMI1-dependent and independent cell cycle check-points.

Authors:  Peggy Prickaerts; Hanneke E C Niessen; Vivian E H Dahlmans; Frank Spaapen; Juliette Salvaing; Jolien Vanhove; Claudia Geijselaers; Stefanie J J Bartels; Iris Partouns; Dietbert Neumann; Ernst-Jan Speel; Yoshihiro Takihara; Bradly G Wouters; Jan Willem Voncken
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

9.  Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma.

Authors:  Sara Westrøm; Tina B Bønsdorff; Nasir Abbas; Øyvind S Bruland; Thora J Jonasdottir; Gunhild M Mælandsmo; Roy H Larsen
Journal:  PLoS One       Date:  2016-10-24       Impact factor: 3.240

Review 10.  Tumour vasculature--a potential therapeutic target.

Authors:  C T Baillie; M C Winslet; N J Bradley
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.